专利检索 ap:("John George Catalano" OR "David Norman Deaton" OR "Aaron Bayne Miller" OR "Francis Xavier Tavares") AND inv:"Aaron Bayne Miller" 第 1 页

1.

发明授权
Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors 失效
标题翻译：可用作组织蛋白酶K抑制剂的环烷基酮酰胺衍生物

公开(公告)号：US07282512B2

公开(公告)日：2007-10-16

申请号：US10501636

申请日：2003-01-15

申请人： John George Catalano , David Norman Deaton , Aaron Bayne Miller , Francis Xavier Tavares

发明人： John George Catalano , David Norman Deaton , Aaron Bayne Miller , Francis Xavier Tavares

IPC分类号： A61K31/41 , C07D233/00

CPC分类号： C07D213/30 , C07C271/22 , C07C271/34 , C07C275/16 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D213/40 , C07D231/40 , C07D233/84 , C07D237/14 , C07D239/34 , C07D239/38 , C07D239/42 , C07D263/58 , C07D277/24 , C07D277/34 , C07D285/08 , C07D295/215 , C07D417/12 , C07D495/04

摘要： Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

摘要翻译： 本文描述了可用作组织蛋白酶K抑制剂的环烷基酮酰胺衍生物。所描述的发明还包括制备这种环烷基酮酰胺衍生物的方法以及使用该方法来治疗与骨质疏松增加相关的疾病（包括骨质疏松症）的方法，其可能最终导致骨折。

2.

发明授权
Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss 失效
标题翻译： 1-（氧代氨基乙酰基）戊基氨基甲酸酯作为组织蛋白酶K抑制剂用于治疗骨丢失的衍生物

公开(公告)号：US07402606B2

公开(公告)日：2008-07-22

申请号：US10510469

申请日：2003-04-01

申请人： David Gene Barrett , John G. Catalano , David Norman Deaton , Aaron Bayne Miller , John A. Ray , Vicente Samano

发明人： David Gene Barrett , John G. Catalano , David Norman Deaton , Aaron Bayne Miller , John A. Ray , Vicente Samano

IPC分类号： A61K31/341 , A61K31/4015 , A61K31/4025 , A61K31/404 , A61K31/4155 , A61K31/416 , A61K31/4192 , A61K31/4196 , A61K31/4245 , A61K31/42 , A61K31/433 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/5377

CPC分类号： C07D207/27 , C07D207/12 , C07D207/273 , C07D207/48 , C07D307/20 , C07D307/33 , C07D401/06 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14

摘要： Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

摘要翻译： 式（I）的杂环取代的酮酰胺衍生物，其中取代基A，D，A和R如权利要求1中所定义，其可用作组织蛋白酶K抑制剂。所描述的发明还包括制备这种杂环取代的酮酰胺衍生物的方法以及在制备用于治疗与骨吸收和形成之间不平衡的疾病（包括骨质疏松症）相关的药物的药物的方法，其可最终导致骨折。

3.

发明授权
Substituted quinoline compounds for use as selective estrogen receptor modulator 失效
标题翻译：用作选择性雌激素受体调节剂的取代喹啉化合物

公开(公告)号：US07405303B2

公开(公告)日：2008-07-29

申请号：US10598246

申请日：2005-02-22

申请人： William Joel Hoekstra , Aaron Bayne Miller , William John Zuercher , Harikrishna Suryakant Patel

发明人： William Joel Hoekstra , Aaron Bayne Miller , William John Zuercher , Harikrishna Suryakant Patel

IPC分类号： C07D215/00 , A61K31/4709

CPC分类号： C07D215/233 , C07C59/68 , C07D215/36

摘要： The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.

摘要翻译： 本发明涉及具有多种治疗用途的新型式（I）化合物，更特别地涉及特别用于选择性雌激素受体调节的新颖取代的喹啉化合物。

4.

发明申请
Cycloalkylidene Compounds As Modulators of Estrogen Receptor 失效
标题翻译：环亚烷基化合物作为雌激素受体的调节剂

公开(公告)号：US20090253659A1

公开(公告)日：2009-10-08

申请号：US12480097

申请日：2009-06-08

申请人： Jing Fang , Dennis Heyer , Aaron Bayne Miller , Frank Navas, III , Terrence Lee Smalley, JR. , William J. Zuercher , Subba Reddy Katamreddy

发明人： Jing Fang , Dennis Heyer , Aaron Bayne Miller , Frank Navas, III , Terrence Lee Smalley, JR. , William J. Zuercher , Subba Reddy Katamreddy

IPC分类号： A61K31/66 , A61K31/19 , A61P15/00

CPC分类号： C07D207/333 , C07C39/23 , C07C39/42 , C07C43/23 , C07C45/45 , C07C45/46 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/71 , C07C47/57 , C07C49/403 , C07C49/83 , C07C49/835 , C07C49/84 , C07C59/54 , C07C59/56 , C07C65/19 , C07C233/25 , C07C235/34 , C07C235/42 , C07C255/13 , C07C255/53 , C07C311/08 , C07C311/21 , C07C317/22 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07D207/16 , C07D211/60 , C07D211/62 , C07D213/30 , C07D239/26 , C07D261/08 , C07D263/32 , C07D295/096 , C07D307/42 , C07D309/20 , C07D309/22 , C07D335/02 , C07F9/4015

摘要： The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.

摘要翻译： 本发明涉及具有多种治疗用途的新化合物，更特别地涉及特别适用于选择性雌激素受体调节的新型取代的环亚烷基化合物。

5.

发明授权
Selective RXR ligands 失效
标题翻译：选择性RXR配体

公开(公告)号：US07173134B2

公开(公告)日：2007-02-06

申请号：US10490805

申请日：2002-09-16

申请人： Curt Dale Haffner , Istvan Kaldor , Darryl Lynn McDougald , Aaron Bayne Miller

发明人： Curt Dale Haffner , Istvan Kaldor , Darryl Lynn McDougald , Aaron Bayne Miller

IPC分类号： C07D491/048 , C07D263/56 , C07D307/80 , C07D307/85 , C07D333/56 , C07D405/04 , C07D411/04

CPC分类号： C07D263/56 , C07D307/54 , C07D333/24 , C07D333/60 , C07D409/04 , C07D491/04

摘要： The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα, RXRβ, or RXRγ. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

摘要翻译： 本发明包括在RXR，目前为RXRα，RXRβ或RXRγ的一种或多种同工型上具有选择性作为RXR激动剂的新型类视色素化合物。因此，本发明化合物和掺入这些化合物的药物组合物在治疗RXR介导的病症中是有效的。在其他生理反应中，本发明的化合物降低血糖并维持体重，因此可用于治疗糖尿病（NIDDIM）和肥胖症。

6.

发明授权
1-phenylalkanone 5-HT.sub.4 receptor ligands 失效
标题翻译： 1-苯基烷酮5-HT 4受体配体

公开(公告)号：US5763458A

公开(公告)日：1998-06-09

申请号：US456168

申请日：1995-05-31

申请人： Robin Douglas Clark , Richard Malcolm Eglen , John Otis Gardner , Alam Jahangir , Aaron Bayne Miller

发明人： Robin Douglas Clark , Richard Malcolm Eglen , John Otis Gardner , Alam Jahangir , Aaron Bayne Miller

IPC分类号： C07D295/10 , A61K31/136 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/40 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/451 , A61P1/00 , A61P9/00 , A61P13/00 , A61P13/02 , A61P15/00 , A61P25/00 , A61P43/00 , C07C225/22 , C07C239/16 , C07C259/10 , C07D207/09 , C07D211/14 , C07D211/20 , C07D211/32 , C07D211/34 , C07D211/46 , C07D211/58 , C07D211/62 , C07D213/46 , C07D295/03 , C07D295/108 , C07D317/58 , C07D317/66 , C07D319/18 , C07D405/06 , C07D487/08

CPC分类号： C07D295/108 , C07C225/22 , C07C259/10 , C07D211/32 , C07D211/34 , C07D211/46 , C07D211/58 , C07D211/62 , C07D317/66 , C07D319/18

摘要： The present invention relates to novel 5-HT.sub.4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C.sub.2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C.sub.1-4)alkyloxy or phenyl(C.sub.1-4)alkyloxy and optionally substituted at its 3-position with (C.sub.1-4)alkyloxy or substituted at its 2- and 3-positions together with methylenedioxy or ethylenedioxy and the highest numbered carbon of the (C.sub.2-6)alkan-1-one is substituted with di(C.sub.1-4)alkylamino, morpholin-1-yl or pyrrolidin-1-yl or optionally substituted piperidin-1-yl, piperidin-4-yl, azacyclohept-1-yl, azabicyclo�2.2.1!hept-3-yl, azabicylo�2.2.2!oct-3-yl or azabicylo�3.2.2!non-3-yl; and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers and methods of using and making such derivatives.

摘要翻译： 本发明涉及5-（5-卤代-4-氨基苯基）（C 2-6）烷-1-酮衍生物的新型5-HT 4受体配体，其中5-卤代-4-氨基苯基在其（C 1-4）烷氧基或苯基（C 1-4）烷氧基，并且其3-位上任选被（C 1-4）烷氧基取代或在其2-和3-位与亚甲二氧基或亚乙二氧基取代，（C2-6）烷基-1-酮的最高编号的碳被二（C 1-4）烷基氨基，吗啉-1-基或吡咯烷-1-基或任选取代的哌啶-1-基，哌啶-4-基，氮杂环庚烯-1-基，氮杂双环[2.2.1]庚-3-基，氮杂双环[2.2.2]辛-3-基或氮杂双环[3.2.2]壬-3-基; 和其药学上可接受的盐，各异构体和异构体的混合物以及使用和制备这些衍生物的方法。